# Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme

> **NCT02331498** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Centre Antoine Lacassagne** · enrollment: 51 (estimated)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** Pazopanib

## Key facts

- **NCT ID:** NCT02331498
- **Lead sponsor:** Centre Antoine Lacassagne
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-06
- **Primary completion:** 2027-02
- **Final completion:** 2030-08
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02331498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02331498, "Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02331498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*